Our data suggested that ANXA6 overexpression made PS-BC cells more resistant to high-dose PTX treatment (Figures 2G–J), and conversely, knockdown of ANXA6 increased PTX sensitivity in PR-BC cells (Figures 2K–N). The gene discussed is ANXA6; the disease is breast cancer.